Low-dose cyclosporin A in severe psoriasis. A double-blind study

Abstract

Twenty patients with severe plaque psoriasis were selected to receive either low‐dose cyclosporin A (CyA) or placebo (CyA vehicle) in a double‐blind randomized trial at two centres. Within 4 weeks the mean reduction in the Psoriasis Area and Severity Index (PASI) in 10 patients receiving CyA (mean dose 5.5 mg/kg/day) differed significantly from the mean reduction in 10 patients receiving placebo. In eight patients given placebo a switch to CyA therapy resulted within 4 weeks in a mean reduction in PASI of 90%. In a total 15 out of 18 patients given CyA (83%) (mean dose 5.6 mg/kg/day) there was an improvement of ≥ 75% in PASI within 4 weeks. In a 2‐month tapering off phase a lower mean CyA dose (3 mg/kg/day) was effective in maintaining the reduced PASI scores in seven of nine patients. Four out of five CyA treated patients who entered a post‐treatment observation phase had a relapse (PASI score ≥ 50% of score at baseline) after a mean interval of 6.5 weeks. The most important side‐effects were mild reversible hypertension in 5 of 18 patients (28%), and reversible elevated serum creatinine levels in 7 of 18 patients (39%). We consider that further studies are justified in severe chronic psoriasis to establish suitable regimens for maintenance of remission in psoriasis with low‐doses of CyA or a combination of CyA with other anti‐psoriatic agents.